Appendix 4D and Half-Year Financial Report
Filed with ASX · · 22 pages · English
Name of entity Cogstate Limited ABN or equivalent company reference ABN 80 090 975 723 Half-year 31 December 2016 (Previous corresponding period: 31 December 2015) Results for announcement to the market Revenue from ordinary activities $18,570,060 Up 42.6% Net Profit Before Tax $1,512,965 Up 37.5% Net profit after tax (from ordinary activities) for the period attributable to members $966,417 Down
Story so far
Earlier from Cogstate
- Cogstate enters into agreement with Clinical Ink
- 2016 Financial Year Results
- Chairmans Address to Shareholders
- JV Agreement Signed
- CogState 2010 AGM Address
Later from Cogstate
- Cogstate selected as preferred provider for Lilly
- FY17 Earnings Update
- Cogstate cleared by FDA to start marketing Cognigram in U.S.
- Interim Business Update
- Global Alzheimer Platform Foundation Selects Cogstate
Follow Cogstate into a list and get an email when it puts out news.
Follow Cogstate